Scientists hunt for clues to stop hepatitis drug without relapse
NCT ID NCT06603311
First seen Mar 06, 2026 · Last updated May 16, 2026 · Updated 11 times
Summary
This study aims to find biological markers that can tell doctors when it is safe for patients with chronic hepatitis delta to stop taking the drug bulevirtide without the virus coming back. Twenty adults with stable liver disease who have been on bulevirtide for at least 48 weeks will stop treatment and be monitored for 48 weeks. Researchers will track which patients experience a return of the virus and look for patterns in their blood to predict this outcome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS D, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité - University Hospital Berlin (Campus Virchow-Clinic); Department of Hepatology and Gastroenterology
Berlin, State of Berlin, 13353, Germany
-
Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico; Division of Gastroenterology and Hepatology
Milan, 20122, Italy
-
Hannover Medical School; Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology
Hanover, Lower Saxony, 30625, Germany
-
University Hospital Frankfurt; Medical Clinic 1
Frankfurt am Main, Hesse, 60590, Germany
-
University Hospital Heidelberg; Department of Internal Medicine IV: Gastroenterology, Hepatology, Infectious Diseases, Poisoning
Heidelberg, Baden-Wurttemberg, 69120, Germany
Conditions
Explore the condition pages connected to this study.